NF-κB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins

Arthritis and Rheumatism

Volumn 52, Issue 7, 2005, Pages 2179-2191

  Todaro, Matilde ^a   Zerilli, Monica ^a   Triolo, Giovanni ^a   Iovino, Flora ^a   Patti, Mariella ^a   Accardo Palumbo, Antonina ^a   Di Gaudio, Francesca ^a   Turco, Maria Caterina ^b   Petrella, Antonello ^b   De Maria, Ruggero ^c,d   Stassi, Giorgio ^a,e  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d Mediterranean Institute of Oncology   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; DEATH RECEPTOR; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; I KAPPA B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; REGULATOR PROTEIN; SMALL INTERFERING RNA; THALIDOMIDE; BCL2L1 PROTEIN, HUMAN; CFLAR PROTEIN, HUMAN; PROTEIN BCL X; SIGNAL PEPTIDE;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BEHCET DISEASE; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; MALE; NUCLEAR LOCALIZATION SIGNAL; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; UPREGULATION;

ADULT; ANTIGENS, CD95; APOPTOSIS; BCL-X PROTEIN; BEHCET SYNDROME; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES, MONONUCLEAR; MALE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; T-LYMPHOCYTES; THALIDOMIDE; TRANSFECTION; UP-REGULATION;

EID: 22244463588     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21145     Document Type: Article

References (56)

1. Serdaroglu P. Behcet's disease and the nervous system. J Neurol 1998;245:197-205.
2. Monastero R, Camarda C, Pipia C, Lopez G, Camarda LK, Baiamonte V, et al. Cognitive impairment in Behcet's disease patients without overt neurological involvement. J Neurol Sci 2004;220:99-104.
3. Rizzi R, Bruno S, Dammacco R. Behcet's disease: an immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 1997;27:225-32.
4. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-80.
5. Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S. Cytokines in Behcet's disease. J Rheumatol 1996;23: 321-2.
6. Triolo G, Accardo-Palumbo A, Dieli F, Ciccia F, Ferrante A, Giardina E, et al. Vγ9/Vδ2 T lymphocytes in Italian patients with Behcet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor β1 expression in active disease. Arthritis Res Ther 2003;5:R262-8.
7. Sun B, Rizzo LV, Sun SH, Chan CC, Wiggert B, Wilder RL, et al. Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J Immunol 1997;159:1004-11.
8. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999;42: 1967-74.
9. Krueger A, Fas SC, Baumann S, Krammer PH. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev 2003;193:58-69.
10. Cohen JJ. Apoptosis. Immunol Today 1993;14:126-30.
11. Cohen JJ. Apoptosis: mechanisms of life and death in the immune system. J Allergy Clin Immunol 1999;103:548-54.
12. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995;16:569-74.
13. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-41.
14. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993;5:625-30.
15. Kirchhoff S, Muller WW, Krueger A, Schmitz I, Krammer PH. TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity. J Immunol 2000;165:6293-300.
16. Liu H, Pope RM. The role of apoptosis in rheumatoid arthritis. Curr Opin Pharmacol 2003;3:317-22.
17. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001;21:8247-54.
18. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-κB signals induce the expression of c-FLIP. Mol Cell Biol 2001;21: 5299-305.
19. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001;21:3964-73.
20. Karin M. How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene 1999;18:6867-74.
21. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
22. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol 2002;2:725-34.
23. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991;173:699-703.
24. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
25. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-α inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996;81:219-23.
26. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-14.
27. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000;108:487-95.
28. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor a and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;50:196-200.
29. Brik R, Shamali H, Bergman R. Successful thalidomide treatment of severe infantile Behcet disease. Pediatr Dermatol 2001;18: 143-5.
30. Yasui K, Misawa Y, Shimizu T, Komiyama A, Kawakami T, Mizoguchi M. Thalidomide therapy for juvenile-onset entero-Behcet disease. J Pediatr 2003;143:692-4.
31. Gockel HR, Lugering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T, et al. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J Immunol 2004;172:5103-9.
32. 2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002;168:2644-51.
33. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 2001;276:22382-7.
34. Criteria for activity of Behcet's disease. In: Sakane T, editor. Annual report of Behcet's disease. Behcet's Disease Research Committee of Japan; 1994.
35. Stassi G, Todaro M, Bucchieri F, Stoppacciaro A, Farina F, Zummo G, et al. Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. J Immunol 1999;162:263-7.
36. De Maria R, Todaro M, Stassi G, di Blasi F, Giordano M, Galluzzo A, et al. Defective T cell receptor/CD3 complex signaling in human type I diabetes. Eur J Immunol 1994;24:999-1002.
37. Stassi G, di Liberto D, Todaro M, Zeuner A, Ricci-Vitiani L, Stoppacciaro A, et al. Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat Immunol 2000;1:483-8.
38. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K, Gaynor RB. TAX1 is critical for IκB kinase-mediated activation of the NF-κB pathway. J Mol Biol 2003;326:105-15.
39. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
40. Refaeli Y, van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998;8:615-23.
41. Kovacs B, Liossis SN, Dennis GJ, Tsokos GC. Increased expression of functional Fas-ligand in activated T cells from patients with systemic lupus erythematosus. Autoimmunity 1997;25:213-21.
42. Xu L, Zhang L, Yi Y, Kang HK, Datta SK. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 2004;10:411-5.
43. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5.
44. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
45. Peter ME, Kischkel FC, Scheuerpflug CG, Medema JP, Debatin KM, Krammer PH. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur J Immunol 1997;27:1207-12.
46. Schmitz I, Krueger A, Baumann S, Schulze-Bergkamen H, Krammer PH, Kirchhoff S. An IL-2-dependent switch between CD95 signaling pathways sensitizes primary human T cells toward CD95-mediated activation-induced cell death. J Immunol 2003;171: 2930-6.
47. Yang P, Chen L, Zhou H, Zhong H, Wang H, Huang X, et al. Resistance of lymphocytes to Fas-mediated apoptosis in Behcet's disease and Vogt-Koyangi-Harada syndrome. Ocul Immunol Inflamm 2002;10:47-52.
48. Yang P, Ji L, Zhou H, Huang X, Xie C, Jin H, et al. Disturbed expression of Fas/FasL on CD4(+) and CD8(+) T cells in Behcet's disease, Vogt-Koyanagi-Harada syndrome, and idiopathic anterior uveitis. Ocul Immunol Inflamm 2001;9:185-91.
49. Nakamura S, Sugita M, Matoba H, Tanaka S, Isoda F, Ohno S. Insufficient expression of Fas antigen on helper T cells in Behcet's disease. Br J Ophthalmol 1996;80:174-6.
50. Ayaslioglu E, Turgay M, Duzgun N, Duman M. Expression of Fas antigen (CD95) on peripheral blood lymphocytes in Behcet's disease. Clin Exp Rheumatol 2000;18:538-40.
51. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
52. Wong HK, Kammer GM, Dennis G, Tsokos GC. Abnormal NF-κB activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol 1999;163:1682-9.
53. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30.
54. Ginsburg PM, Dassopoulos T, Ehrenpreis ED. Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature. Ann Med 2001;33:516-25.
55. Ossandon A, Cassara EA, Priori R, Valesini G. Thalidomide: focus on its employment in rheumatologic diseases. Clin Exp Rheumatol 2002;20:709-18.
56. Ma W, Gee K, Lim W, Chambers K, Angel JB, Kozlowski M, et al. Dexamethasone inhibits IL-12p40 production in lipopolysaccharide-stimulated human monocytic cells by down-regulating the activity of c-Jun N-terminal kinase, the activation protein-1, and NF-κB transcription factors. J Immunol 2004;172:318-30.